What do U.S. biopharmaceutical companies get from patents and research and development spikes for their dynamic corporate performance?

Wang, Wei‐KangLu, Wen‐MinKweh, Qian LongTruong, Hoang Tu Nhi2020-02-252020-02-2520202020-07-01Wang, W., Lu, W., Kweh, Q. L., & Truong, H. T. N. (2020). What do U.S. biopharmaceutical companies get from patents and research and development spikes for their dynamic corporate performance?. Managerial and Decision Economics, 41(5), 762-770. https://doi.org/10.1002/mde.313501436570http://hdl.handle.net/20.500.12519/164https://doi.org/10.1002/mde.3135enIntellectual Property-RightsMarket ValueOperating PerformanceContextual VariablesFirm ValueInnovationEfficiencyProductivityInvestmentImpactWhat do U.S. biopharmaceutical companies get from patents and research and development spikes for their dynamic corporate performance?ArticleCopyright : 2020 John Wiley & Sons, Ltd.